The Global Market for Anticoagulants is Projected to Reach US$30 Billion by 2020

Rising Demand for Novel Oral Anticoagulants (NOACs) Drives the Global Anticoagulants Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Anticoagulants market. The global market for Anticoagulants is projected to reach US$30 billion by 2020, driven by the rising popularity of novel oral anticoagulants that overcome the limitations of traditional warfarin in the treatment of cardiac disorders and venous thromboembolism.

Anticoagulants, by preventing blood clots, find use in the treatment of several diseases, including deep venous thromboembolism, pulmonary embolism, Atrial Fibrillation (AF), unstable angina, as well as heart attack, and stroke. The global anticoagulants market is significantly boosted by aging population and related afflictions, including cardiovascular disease and orthopedic disorders, which are the main conditions that require anticoagulation therapy. Anticoagulants have emerged as a critical therapy in the prevention of venous thromboembolism (VTE) following major orthopedic surgeries, such as elective knee or hip replacement surgery, and stroke and systemic embolism in AF patients, all of which carry a high risk of mortality.

While the conventional treatments for anticoagulation include Coumadin (warfarin) and heparin, the Vitamin K-dependent mechanism of action of warfarin was ridden with many disadvantages, such as dietary and drug interactions, and the need for constant dosage monitoring. Use of injectable heparins caused hemorrhage, osteoporosis and thrombocytopenia, among other issues. The new Novel oral anticoagulants (NOACs), introduced after 2010, witnessed favorable commercial success. NOACs showed direct thrombin/Factor Xa inhibition mechanism and high efficacy, without dosage and administration issues. The new classes of oral drugs that are greatly impacting the market include Direct Factor Xa inhibitors rivaroxaban (Bayer’s Xarelto) and apixaban (Eliquis, developed by Bristol Myers Squibb in collaboration with Pfizer); and the thrombin inhibitor, dabigatran (Boehringer Ingelheim’s Pradaxa). FDA’s approval of Daiichi Sankyo’s edoxaban (Savaysa) in 2015 added a fourth drug to the NOAC race. The FDA approval of newer anticoagulant brands and expanded indications of older brands are fueling better market access and growth. Increased R&D in this area is expected to further boost growth. In addition, better reimbursement and payer policies are also contributing to market growth.

The traditional market for anticoagulants, including Warfarin and Heparin, is inundated with generic drugs with almost all of the major branded drugs having lost their patent protection. Presently, both branded and generic warfarin and heparins co-exist in the market, with the market skewed substantially in favor of generics. In the NOAC category, there is no threat of generics till 2018, when Boehringer Ingelheim’s patent on Pradaxa expires. The new guidelines by National Institute for Health and Care Excellence (NICE) for AF management promote increased use of NOACs and deter aspirin usage, further favoring the market for novel oral anticoagulants. The NOAC market, however, was restrained by the lack of an appropriate antidote to treat bleeding emergencies. However, the recent approval of Praxbind (antidote to Pradaxa) and ongoing final phase clinical trials for other antidotes are expected to turn the tide again in favor of NOACs.

As stated by the new market research report on Anticoagulants, the United States represents the largest market worldwide, supported by increasing incidence of cardiac disorders, including AF and stroke, and higher awareness about anticoagulants and their therapeutic applications. Asia-Pacific ranks as the fastest growing market with a projected compounded annual growth rate of 10.3% over the analysis period. The growth in the region is supported by growing population and a parallel increase in healthcare needs, developing healthcare infrastructure, and improved access to affordable healthcare. Oral anticoagulants are expected to drive future growth in the market, while injectable anticoagulants are forecast to decline over the analysis period.

Major players covered in the report include Abbott India Limited, Aspen Holdings, Bayer Healthcare AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eisai Inc., GlaxoSmithKline Plc., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Sanofi S.A., and Teva Pharmaceutical Industries Ltd., among others.

The research report titled “Anticoagulants: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the market trends, market issues, growth drivers, and strategic industry activity of global companies.  The report provides market estimates and projections for major geographic markets, including the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), Latin America (Brazil, and Rest of Latin America), and Rest of World. Product types analyzed include Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin). 

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.